科研論文是對科學領域中的問題進行總結、研究、探討，表述科學研究成果的論文，下面是小編蒐集整理的SCI論文格式及投稿注意事項，歡迎閱讀檢視。
一：論文的文題
作用
反映論文的主題或主要資訊
吸引讀者
要求
一般不超過100個字母
排版後不超過2行
可以不是完整的句子
最好反映文章的特色，如：若是隨機對照試驗，文題需要體現
最好反映研究物件，如動物種類等
二：關鍵詞
一般列出3~10個,應儘量按照美國國立醫學圖書館編纂的《Index Medicus》中的MeSH表選詞。
如果MeSH表中找不到，可以用新詞或相近的詞
三：論文摘要
200-300字
一般為四要素結構式，包括Objective (Background), Methods, Results, Conclusion
JAMA分Context, Objective, Design and setting, Patients, Interventions， Main outcome measures, Results, Conclusions
目的(背景)
Background Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis.
方法
Methods Seventy-four patients with HCV-related cirrhosis and platelet counts of 20,000 to less than 70,000 per cubic millimeter were randomly assigned to receive eltrombopag (30, 50, or 75 mg daily) or placebo daily for 4 weeks. The primary end point was a platelet count of 100,000 per cubic millimeter or more at week 4. Peginterferon and ribavirin could then be initiated, with continuation of eltrombopag or placebo for 12 additional weeks.
結果
Results At week 4, platelet counts were increased to 100,000 per cubic millimeter or more in a dose-dependent manner among patients for whom these data were available: in 0 of the 17 patients receiving placebo, in 9 of 12 (75%) receiving 30 mg of eltrombopag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiving 75 mg of eltrombopag (P<0.001). Antiviral therapy was initiated in 49 patients (in 4 of 18 patients receiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag) while the administration of eltrombopag or placebo was continued. Twelve weeks of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the placebo group. The most common adverse event during the initial 4 weeks was headache; thereafter, the adverse events were those expected with interferon-based therapy.
結論
Conclusions Eltrombopag therapy increases platelet counts in patients with thrombocytopenia due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy.
四：論文引言
需要交待研究的背景
需要交待本文要做什麼
需要引用相關參考文獻
300字左右
In this phase 2 study, we assessed whether the use of eltrombopag can increase platelet counts in patients with thrombocytopenia associated with cirrhosis due to chronic HCV infection. The safety and adverse-event profiles of eltrombopag were also evaluated.
五：材料和方法
應明確說明選擇的觀察或實驗物件(患者或實驗動物，包括對照)
描述受試者的年齡、性別和其他重要特徵，明確研究物件是如何選擇的`。
應說明研究的地點，以及診斷、納入和剔除標準。
詳細介紹研究方法、儀器和操作程式。
使用已有的方法，應標明參考文獻;對已經發表但大家不是很熟悉的方法，不僅要給出參考文獻，還要做簡要說明;如使用的是新的或經過修改的方法，應說明使用的原因，並評價其侷限性。
對使用的藥物或化學制品，應介紹其通用名稱、劑量和使用途徑。
第一次描述產品時，要交代生產廠家和國家名稱
應簡要介紹所採用的統計學分析方法、採用的軟體及版本，並註明檢驗水準。
材料與方法交代的是否清楚，要看讀者看後能重複試驗。
Primary and Secondary End Points
The primary end point was the proportion of patients who had door-to-balloon times within the 90-minute recommended guideline. …
Secondary end points included mortality, reinfarction, stroke, cardiogenic shock, and major bleeding. …
Statistical Analysis
Categorical variables were compared with the use of Fisher's exact test. Normally distributed continuous variables were compared with Student's t-test. Time intervals were analyzed with the Mann–Whitney U test. Analyses were conducted with the use of Systat software, version 11.0 (Systat). A P value of 0.05 or less was considered to indicate statistical significance.
六：論文結果
應圍繞研究的主題，用文字、圖表有邏輯地、有層次地列出。
先主要結果，後次要結果
能用圖表的儘量用圖表。
圖表所示與文字表述儘量不要重複。
對於與研究假設或與研究者的主觀願望相違的結果，也應如實報告，不能隨意取捨。
要根據結果下結論，而不是根據結論安排結果。
作者有義務報告陰性結果
要重視對失訪者的追蹤和描述(intention-to-treat analysis)
Results
Characteristics of the Patients
Between May 1, 2005, and April 30, 2006, a total of 344 patients with confirmed ST-segment elevation myocardial infarction were referred for primary PCI to the cardiac care center.
七：論文的討論
第一段要指出本研究的重要結果和新發現
要把本結果和國內外其他相關結果進行分析，指出和其它研究的異同及原因
要指出本研究的不足
最後做小結和展望
Discussion
We identified regions of rare copy-number variation in families with autism and observed an association between a microdeletion on chromosome 16 (and the inherited reciprocal duplication) and autism. …
Several limitations of our trial should be mentioned. The vasopressin was infused over a set range of doses, and we did not measure vasopressin levels as a guide to the dose or the duration of infusion. …
In conclusion, our data indicate that a region of chromosome 16p11.2 influences susceptibility to autism when it is either deleted or duplicated. …